Jaguar Animal Health Inc (JAGX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

200 PINE STREET SUITE 400 SAN FRANCISCO, CA 94104

Jaguar Health, Inc. operates as a natural-products pharmaceutical company. The Company engages in development and commercialization of gastrointestinal prescription products for humans and animals, as well as non-prescription gastrointestinal products for animals. Jaguar Health serves human and animal health market worldwide.

Data as of 2020-10-17
Market Cap17.005 Million Shares Outstanding56.123 Million Avg 30-day Volume7.11 Million
P/E Ratio0.2 Dividend Yield EPS1.36
Price/Sales3.066 Price cash flow ratio Price free cash flow ratio-1.5
Book Value0.01 Price to Tangible Book-0.7 Alpha-0.12
Short Interest Ratio % Short Interest to Float R-squared0.021952
BETA0.906734 52-week High/Low1.22 / 0.2839 Stddev0.262827
View SEC Filings from JAGX instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 16 11 45.45% 3 (0.2%) 0 (0.0%)
13F shares: 405.568 Thousand 166.783 Thousand 143.17% 186.908 Thousand 0
% Ownership 1.2596 0.7952 58.4% 0.5805 0.0
New Positions: 7 4 75.0% 3
Increased Positions 3 1 200.0%
Closed Positions 2 2 0.0%
Reduced Positions
Total Calls 0 0
Total Puts 0 0
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding JAGX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding JAGX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KING STEVEN R. EXECUTIVE VP AND SECRETARY

  • Officer
0 2020-03-20 1

CONTE LISA A CHIEF ACCOUNTING OFFICER

  • Officer
  • Director
0 2020-03-20 1

BOCHNOWSKI JAMES J

  • Director
0 2020-03-20 1

MICEK JOHN

  • Director
0 2020-03-20 1

SIEGEL JONATHAN B.

  • Director
0 2020-03-20 1

DIVIS GREGORY J

  • Director
0 2020-03-20 1

LIZAK CAROL R. CHIEF ACCOUNTING OFFICER

  • Officer
0 2020-03-20 1

WOLIN JONATHAN S. CHIEF OF STAFF, CCO & GC

  • Officer
0 2020-03-20 1

JOHNSON JEFFERY C.

  • FORMER DIRECTOR
0 2020-02-21 1

MACNAUGHTAN MURRAY DAVID

  • FORMER DIRECTOR
0 2020-02-21 1

WRIGHT KAREN STEIL CFO AND TREASURER

  • Officer
0 2019-07-24 0

SAGARD CAPITAL PARTNERS, L.P.

SAGARD CAPITAL PARTNERS GP, INC.

SAGARD CAPITAL PARTNERS MANAGEMENT CORP

  • FORMER 10% BENEFICIAL OWNERFORMER 10% BENEFICIAL OWNERFORMER 10% BENEFICIAL OWNER
0 2019-07-23 0

EZRALOW BRYAN

BRYAN EZRALOW 1994 TRUST DATED DECEMBER 22, 1994

  • FORMER 10% OWNERFORMER 10% OWNER
No longer subject to file 2018-10-04 0

NANTUCKET INVESTMENTS LTD

BURFORD CAPITAL LTD

  • 10% Owner
No longer subject to file 2018-09-25 0

GLASER JONATHAN M

  • FORMER 10% OWNER
No longer subject to file 2018-09-25 0

QIU JIAHAO

  • Director
0 2018-03-12 0

YANG ZHI

  • Director
No longer subject to file 2018-03-12 0

KAMPHUIS FOLKERT W.

  • Director
No longer subject to file 2018-03-12 0

AZHIR ARI

  • Director
No longer subject to file 2018-03-12 0

WALTZMAN ROGER J. CHIEF SCIENTIFIC OFFICER

  • Officer
0 2016-12-19 0

BRIANCEAU PHILIPPE CHIEF VETERINARY OFFICER

  • Officer
0 2016-04-01 0

KALLASSY JOHN A CFO, COO, TREASURER

  • Officer
0 2015-05-18 0

HAUSER MICHAEL CHF VETERINARIAN, CLINICAL OPS

  • Officer
0 2015-05-18 0

BVCF MANAGEMENT, LTD.

KUNLUN PHARMACEUTICALS, LTD.

BVCF III, L.P.

BVCF III-A, L.P.

  • 10% Owner
1,522,881 2015-05-18 0

NAPO PHARMACEUTICALS INC

  • 10% Owner
2,666,666 2015-05-13 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments